Question 1

What side effects did the retatrutide trials record?

Accepted Answer

Gut symptoms, and more of them at higher amounts. The 2023 phase 2 obesity trial reported that the most common adverse events in the retatrutide groups were gastrointestinal. The same report records that these events were dose-related, were mostly mild to moderate in severity, and were partially mitigated with a lower starting dose (2 mg vs. 4 mg). A 2025 systematic review of 26 randomised trials in this family names the symptoms. Across those trials the gut events were most commonly nausea, vomiting, diarrhea, and constipation, and they made up the bulk of everything participants reported. Two things are worth holding on to. Dose-related means the rate climbed with the amount assigned, so a figure from the largest arm is not a figure for the whole trial. And mild to moderate is an investigator's grading scale rather than a description of how anybody felt, which is a separate question no study among the research behind this page has published.

Question 2

How many people stopped because of side effects?

Accepted Answer

Fewer than the symptom rates suggest, and the published range across this family is extraordinarily wide. A 2025 systematic review reports AEs requiring treatment discontinuation (0% to 26% vs. 0% to 9%, respectively) against placebo, where AE is the standard shorthand investigators use for an adverse event. The same review sets SAEs (0% to 10% vs. 0% to 12%, respectively) beside them, and describes both categories as rare. Read the placebo columns next to each figure. In some of those trials the serious events were counted more often among participants receiving a dummy injection than among those receiving an active compound, which is what a wide range across a small collection of trials looks like. The retatrutide trials report completion rather than cause. The 2023 phase 2 diabetes trial recorded that 237 (84%) participants completed the study and 222 (79%) completed study treatment. Why the remainder stopped was never broken out, so the distance between those two percentages is a number with no explanation attached to it.

Question 3

Does retatrutide raise heart rate?

Accepted Answer

It did in the one trial that measured it, and the shape of the change over time is the genuinely useful part. In the phase 2 obesity trial, dose-dependent increases in heart rate peaked at 24 weeks and declined thereafter. Two phrases in that sentence carry the finding. Dose-dependent means the rise tracked the amount a participant had been assigned, so a single figure does not apply equally across every arm of the trial. Peaked and then declined means the reading was not a straight line across the full 48 weeks, so any summary number would misdescribe the trajectory it came from. What the published record does not contain is a blood-pressure table, a count of cardiac events, or any outcome measured in people who already have established heart disease. The registry carries a completed phase 3 study in participants with obesity and cardiovascular disease, and nothing from it has been published. Completed describes the administrative stage of a study rather than a result anybody can read.

Question 4

Can retatrutide cause elevated liver enzymes?

Accepted Answer

Nothing among the research behind this page reports a liver-enzyme reading for retatrutide, so that question has no measured answer. What the investigators measured in the liver was fat, a different property of the same organ. A 2024 phase 2a substudy assigned participants (n = 98) who already carried at least a tenth of the organ as fat. Its authors call that condition metabolic dysfunction-associated steatotic liver disease. In that group the relative change from baseline in liver fat at 24 weeks was -42.9% (1 mg), -57.0% (4 mg), -81.4% (8 mg), -82.4% (12 mg) and +0.3% (placebo). The placebo arm barely moved, which is the comparison every one of those figures was measured against. Even so, fat visible on a scan and cellular injury visible in a blood test are different questions, and only the first was ever asked here. A 2025 review of the retatrutide record describes improvements in liver steatosis, meaning fat stored in the liver, and names no enzyme measurement alongside them.

Question 5

Which safety questions does the wider class carry?

Accepted Answer

A 2024 review in Diabetes Care sets the list out in one sentence, and it is longer than most summaries of this family admit. Its author discusses data that inform safety, focusing on muscle strength, bone density and fractures, exercise capacity, gastrointestinal motility, retained gastric contents and anesthesia, pancreatic and biliary tract disorders, and the risk of cancer. That is nine separate questions. Retained gastric contents and anesthesia is the one worth translating: food still sitting in a stomach that empties slowly becomes a problem if somebody is sedated for surgery. None of the nine carries a retatrutide figure among the research behind this page. The same review places the compound in the family by how it is built, noting that retatrutide and survodutide enable simultaneous activation of the glucagon and GLP-1 receptors. A question raised about a class of compounds is not an answer about one member of it, and the second has to be measured on its own.

Question 6

Does retatrutide interact with any medications?

Accepted Answer

One interaction study has been run, and no result from it has been published. The registry lists a phase 1 entry, To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants, in thirty people, marked as completed. Pharmacokinetics means how much of a dose reaches the blood and how quickly it clears; metoprolol is a common heart-rate and blood-pressure medicine. The trials themselves support one modest inference. The 2023 phase 2 diabetes trial enrolled people who were treated with diet and exercise alone or with a stable dose of metformin (≥1000 mg once daily) for at least 3 months before the screening visit. Metformin was therefore taken alongside retatrutide under supervision, by people whose other conditions had been screened first. Everything else is untested rather than cleared. No interaction programme has been published for this compound, because such a programme is one of the things an approval requires.

Question 7

Could retatrutide cause low blood sugar?

Accepted Answer

Two registered studies were built around that exact question, and neither has published a result. One looks at the response of people with type 2 diabetes on once-weekly retatrutide to hypoglycemia, which means blood sugar falling below a safe range. It is a phase 1 entry in eighty people and it is marked as completed. A second entry studies the effect of retatrutide on insulin secretion and insulin sensitivity, in ninety-five adults, and it is still open. The trials that have reported measured an average instead. The 2026 phase 3 trial tested retatrutide as a monotherapy in people with type 2 diabetes, and it reported the mean change in a blood-sugar average that covers about three months. An average across forty weeks cannot show a single bad hour, and those are different questions.

Question 8

Who was excluded from the retatrutide trials?

Accepted Answer

Entry criteria are published for all of these trials, and they describe whose bodies produced these numbers. The 2023 phase 2 obesity trial took adults who had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of 30 or higher or who had a BMI of 27 to less than 30 plus at least one weight-related condition. The diabetes trials drew tighter boundaries still. The phase 2 trial required adults aged 18-75 years with type 2 diabetes, glycated haemoglobin (HbA1c) of 7·0-10·5% (53·0-91·3 mmol/mol), and BMI of 25-50 kg/m2, where HbA1c is a blood-sugar average covering roughly three months. The 2026 phase 3 trial recruited adults (aged ≥18 years) with type 2 diabetes that is inadequately controlled by diet and exercise alone. So nobody under eighteen was studied, nobody over seventy-five appears in the phase 2 diabetes work, and nobody of ordinary weight was enrolled anywhere. Those groups were not examined and found to be at risk; they were never measured at all, which is a different statement and a much weaker one.

Question 9

Who should not take retatrutide?

Accepted Answer

Nobody has published a list, and the reason is the missing approval rather than an oversight. A list of people warned off a compound is part of a label, a label belongs to something a regulator has cleared, and a 2025 systematic review still counts retatrutide among 9 premarket agents for long-term weight management. What stands in place of that list is the entry criteria above, plus the groups the programme has never reached. A 2026 paper describing the late-stage studies says they assess weekly subcutaneous retatrutide compared to placebo, in conjunction with healthy diet and physical activity in over 5800 participants, every one of them an adult recruited against written criteria. So the honest answer is a map of who was studied rather than a roster of who was warned off. Those are different questions, and only the first has published material behind it. Anyone outside that map is unstudied, and unstudied is neither a clearance nor a caution.

Question 10

Are the side effects different for women?

Accepted Answer

Nothing among the research behind this page splits adverse-event reporting by sex, although women outnumbered men across the wider literature. A 2025 systematic review of 26 randomised trials describes a pooled group of 15 491 participants (72% female). The retatrutide trials were more evenly balanced than that. The 2023 phase 2 obesity trial enrolled 338 adults, 51.8% of whom were men, and the 2026 phase 3 diabetes trial randomised 537 (296 [55%] female and 241 [45%] male) adults. Pregnancy and breastfeeding are the clearest holes in the record. No trial among the research behind this page reports an outcome in a pregnant participant, and nothing describes what might reach a nursing infant. A gap that wide is a reason the question stays open rather than evidence pointing either way.

Question 11

What is known about long-term side effects?

Accepted Answer

Very little, and the limit is the length of these trials rather than a shortage of participants. The longest published retatrutide course runs 48 weeks of weekly injection, and the phase 3 diabetes trial ran forty weeks. Reviewers of the field say as much in their own words. A 2025 systematic review records that long-term follow-up data on the safety and efficacy of weight maintenance are needed. The same review adds that data on mortality and obesity-related complications, such as cardio-renal-metabolic events, are needed. Read what that second sentence gives up. Deaths, and heart, kidney and metabolic events, are the outcomes people most want settled, and they are listed as needed rather than as reported. A 2025 review of the pipeline frames the same hole from the other side, calling maintenance of the weight loss the outstanding question and noting that treatment may need to be life-long.

Question 12

Is it safe to inject retatrutide outside a trial?

Accepted Answer

We cannot tell anybody an injection carries no risk, and underneath that gap sits a second one. Every figure on this page came from material supplied by a sponsor inside a registered study, where the four late-stage trials are described as multicenter, randomized, double-blind studies with the contents of each syringe established in advance. The one public record of material prepared outside that arrangement is an enforcement entry. The FDA database holds a Class II recall of Retatrutide for Injection, 60mg / 10mL vial, all presentations, filed under lack of assurance of sterility. Sterility is a property of how something was made, and it cannot be judged by looking through glass. So the adverse events counted in these trials describe one kind of material, and nothing among the research behind this page describes the other. Those are different questions, and only the first of them has ever been measured.

Question 13

Is retatrutide legal in the USA?

Accepted Answer

No regulator has approved it, and that single fact governs the rest. A 2025 systematic review counts it among 14 ongoing phase 3 trials, which is a description of a compound still being tested rather than one cleared for use. Not approved is not the same as scheduled, banned or criminalised. Nothing among the research behind this page describes a controlled-substance listing, a sporting prohibition or any statute naming retatrutide, and we will not publish a legal reading we cannot point at a source for. What the record does establish is narrower and more useful. A 2025 review of the pipeline places retatrutide among compounds that have also progressed to phase 3 trials as obesity treatments, and nothing at that stage can lawfully be dispensed by a pharmacy. Approval status and legal status are different questions, and only the first has a published answer here.

Question 14

Has anyone reported a serious problem on retatrutide?

Accepted Answer

Serious events were counted in these trials, and the counts are low and imprecise at the same time. A 2025 systematic review lists its safety outcomes as death, serious adverse events (SAEs), any adverse events (AEs), and gastrointestinal AEs, which is the full set of things it looked for across 26 randomised trials. The 2026 phase 3 trial sums up its own record in a single clause, reporting an adverse event profile consistent with molecules with GLP-1 agonist activity. That is a comparison against a family of compounds rather than a count, and it is as much detail as a trial conclusion carries. What does not exist is the record an approval would generate. With no approval there is no post-marketing reporting system, so every adverse event counted so far happened to a few thousand monitored participants inside fixed windows. Harms that are rare, slow, or specific to people these trials never enrolled would not appear there.

Retatrutide side effects and safety data